Insulet Corporation PODD has witnessed strong momentum in the past year. Shares of the company have risen 78.5% compared with 7.3% growth of the industry during the same time frame. The S&P 500 ...

ACTON, Mass., May 23, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today ...

On another note, Citi removed Insulet from its Top Pick list, although it still holds a Buy rating and raised the price target to $380 from $320, reflecting strong year-to-date performance.

Insulet PODD has outperformed the market over the past 15 years by 10.91% on an annualized basis producing an average annual return of 22.7%. Currently, Insulet has a market capitalization of $22. ...

On Tuesday, Raymond James raised its price target on Insulet Corporation (NASDAQ: PODD), a medical device company, from $328.00 to $360.00, while reiterating an Outperform rating on the shares.The ...

On Tuesday, Raymond (NSE: RYMD) James raised its price target on Insulet Corporation (NASDAQ: PODD), a medical device company, from $328.00 to $360.00, while reiterating an Outperform rating on the ...

The analysts cited the accelerating adoption of patch pump technology, where Insulet Corporation (NASDAQ:PODD) happens to be the sole player in the market. Therefore, this unique position is ...

↗️ Insulet (PODD): Surging revenue and the announcement of new share buybacks pushed the insulin pump maker's stock up by as much as 20%. ↘️ Expedia (EXPE): The online travel agency ...

Fintel reports that on May 30, 2025, Goldman Sachs initiated coverage of Insulet (NasdaqGS:PODD) with a Buy recommendation. Analyst Price Forecast Suggests 0.54% Downside As of May 6, 2025 ...

Explore Insulet stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for PODD. As the broader market stages a sharp rebound from its April lows, several sectors ...

Citi, while removing Insulet from its Top Pick list, increased its price target from $320 to $380, reflecting strong performance and growth potential. Bernstein also raised its price target to $375, ...

On June 4, TD Cowen has lifted its price target on Insulet Corporation (NASDAQ:PODD) to $379 from $324 while reiterating a Buy rating, pointing to strong early-year performance and recent ...